ADHERENCE BARRIERS BETWEEN BIOLOGIC VERSUS NON-BIOLOGIC-TREATED PATIENTS WITH SEVERE ASTHMA: A MULTICENTER STUDY IN GREECE
Author(s)
Ioannis John Yfantopoulos, II, DPhil1, Jannis Constantinidis, Ph.D.2, Michael Makris, Ph.D.3, Constantinos, Glynos, Doctorate4, Vasiliki Stamatopoulou, doctorate4, Maria Pastra, Master of Science4, Loukidis Stelios5.
1University of Athens, Ekali, Greece, 2Aristotle University of Thessaloniki, Thessaloniki, Greece, 3Medical School, National and Kapodistrian University of Athens, Athens, Greece, 4GSK Pharmaceuticals Greece, Athens, Greece, 5National and Kapodistrian University of Athens Medical School, Greece.
1University of Athens, Ekali, Greece, 2Aristotle University of Thessaloniki, Thessaloniki, Greece, 3Medical School, National and Kapodistrian University of Athens, Athens, Greece, 4GSK Pharmaceuticals Greece, Athens, Greece, 5National and Kapodistrian University of Athens Medical School, Greece.
OBJECTIVES: Medication non-adherence is common in severe asthma (SA) and contributes to suboptimal disease control. This study examined adherence barriers between biologic and non-biologic treated patients in the Greek specialist care.
METHODS: This multicentre, cross-sectional, observational survey recruited adults with specialist-confirmed SA who had been treated for ≥2 years in Greece between November 2025 and March 2026. Chi-square test and Mann-Whitney rank-sum tests conducted to assess adherence barriers between biologic and non-biologic treated patients. A Multivariable linear regression model with robust standard errors examined whether biologic use was independently associated with ASK-12 total score barriers after adjusting for multiple socioeconomic and clinical factors.
RESULTS: The analytic sample comprised 442 adults with SA. Biologic compared to non-biologic treated patients had significantly lower ASK-12 total barrier score (median 23.0 vs 30.0, p<0.001).] as well as in the ASK-12 subscales: i. inconvenience of dosing/forgetfulness of medication (median 7.0 vs 9.0, p<0.001), ii. health beliefs/support (median 5.0 vs 7.0, p<0.001), iii. medication-taking behavior/access to care (median 11.0 vs 13.0, p=0.001). After multivariable adjustment modelling, biologic therapy remained independently associated with lower ASK-12 total score (β=-3.25, 95% CI -5.04 to -1.46; p<0.001).
CONCLUSIONS: In this Greek real-world cohort, biologic-treated patients with SA reported with less barriers to adherence than non-biologic treated patients. The adjusted findings strengthen the evidence that biologic-supported care pathways are associated with lower adherence-related barriers
METHODS: This multicentre, cross-sectional, observational survey recruited adults with specialist-confirmed SA who had been treated for ≥2 years in Greece between November 2025 and March 2026. Chi-square test and Mann-Whitney rank-sum tests conducted to assess adherence barriers between biologic and non-biologic treated patients. A Multivariable linear regression model with robust standard errors examined whether biologic use was independently associated with ASK-12 total score barriers after adjusting for multiple socioeconomic and clinical factors.
RESULTS: The analytic sample comprised 442 adults with SA. Biologic compared to non-biologic treated patients had significantly lower ASK-12 total barrier score (median 23.0 vs 30.0, p<0.001).] as well as in the ASK-12 subscales: i. inconvenience of dosing/forgetfulness of medication (median 7.0 vs 9.0, p<0.001), ii. health beliefs/support (median 5.0 vs 7.0, p<0.001), iii. medication-taking behavior/access to care (median 11.0 vs 13.0, p=0.001). After multivariable adjustment modelling, biologic therapy remained independently associated with lower ASK-12 total score (β=-3.25, 95% CI -5.04 to -1.46; p<0.001).
CONCLUSIONS: In this Greek real-world cohort, biologic-treated patients with SA reported with less barriers to adherence than non-biologic treated patients. The adjusted findings strengthen the evidence that biologic-supported care pathways are associated with lower adherence-related barriers
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO178
Topic
Clinical Outcomes, Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Clinical Outcomes Assessment
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)